[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-myocardial-infarction-ami\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-myocardial-infarction-ami":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,49,87,115,149,180,209,235,264,284,315,344,373,396,424,445,483,505,528,548,578,605,632,659,684],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100652619","phase-2-combined-antioxidant-therapy-for-acute-myocardial-infarction-100652619",false,"NCT07776288","Combined Antioxidant Therapy for Acute Myocardial Infarction","Pharmacological Protection Against Reperfusion Injury in Patients With Acute Myocardial Infarction: a Phase 2 Randomized Controlled Trial of a Combined Antioxidant Therapy (CAT-AMI Trial)","CAT-AMI","Inclusion Criteria:\n\n* Age 18 years or older\n* First anterior ST-segment elevation myocardial infarction (STEMI)\n* Symptom onset within 6 hours before presentation\n* Eligible for primary percutaneous coronary intervention (PCI)\n* Provision of informed consent by the participant or a legally authorized representative, according to local ethics requirements\n\nExclusion Criteria:\n\n* Prior myocardial infarction\n* Cardiogenic shock, defined as Society for Cardiovascular Angiography and Interventions (SCAI) shock class D or E.\n* Prior thrombolytic therapy for the index event.\n* Chronic kidney disease, defined as serum creatinine greater than 1.5 mg\u002FdL or dialysis.\n* Liver cirrhosis\n* Advanced heart failure, defined as New York Heart Association (NYHA) class III or IV\n* Glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* Nephrolithiasis\n* Life expectancy less than 6 months\n* Implanted cardiac device, including pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization device\n* Prior coronary artery bypass graft (CABG) surgery\n* Pregnancy\n* Claustrophobia\n* Other contraindications to cardiac magnetic resonance imaging (CMR), according to local protocol","ALL","18 Years",{"count":21,"type":22},46,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this clinical trial is to learn if a combined antioxidant therapy (CAT) can reduce heart damage caused by the return of blood flow after blocked arteries are reopened in adults with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\n1. Does combined antioxidant therapy lower infarct size, measured by cardiac magnetic resonance imaging (CMR), compared with placebo?\n2. Does combined antioxidant therapy improve heart function, blood biomarkers of heart injury, and short-term clinical outcomes?\n3. What problems do participants have when receiving the therapy?\n\nResearchers will compare CAT to placebo (a look-alike infusion with no active drug) to see if the treatment lowers infarct size after STEMI.\n\nParticipants will:\n\n* Be randomly assigned to receive either CAT or placebo\n* Receive the study infusion before and during primary PCI, in addition to standard treatment for STEMI\n* Have blood tests to measure heart injury, oxidative stress, inflammation, and drug levels\n* Undergo cardiac magnetic resonance imaging about 3 to 7 days after STEMI.\n* Be followed for clinical outcomes and safety for 30 days.",[28,29,30],"Acute Myocardial Infarction (AMI)","ST Elevation (STEMI) Myocardial Infarction","Reperfusion Injuries, Myocardial",[32,33,34,35,30],"Antioxidant Therapy","Acute Myocardial Infarction","Randomized Controlled Trial","Oxidative stress","NOT_YET_RECRUITING","2026-08-16",{"date":39,"type":40},"2026-08-20","ACTUAL",{"date":42,"type":22},"2026-09-01",{"date":44,"type":22},"2027-12-31",{"name":46,"class":47},"University of Chile","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":48},"100651657","routine-microaxial-heart-pump-support-and-protocolized-pulmonary-artery-catheter-monitoring-versus-standard-care-in-heart-attack-related-cardiogenic-shock-100651657","NCT07762560","Routine Microaxial Heart Pump Support and Protocolized Pulmonary Artery Catheter Monitoring Versus Standard Care in Heart Attack-Related Cardiogenic Shock","Routine Microaxial Flow Pump Versus Radial Access Revascularization Without Routine Microaxial Flow Pump in Infarct-Related Cardiogenic Shock & Routine Pulmonary Artery Catheterization-based Monitoring With Protocolized Hemodynamic Optimization Versus Simplified Monitoring Without Protocolized Hemodynamic Optimization in Infarct-Related Cardiogenic Shock","DOUBLE-SHOCK","Inclusion Criteria:\n\nCardiogenic shock complicating AMI (STEMI or NSTEMI) plus obligatory all 4 of these:\n\n1. Planned immediate angiography and revascularization (preferred PCI)\n2. Systolic blood pressure \\\u003C100 mmHg or catecholamines required to maintain pressure \\>90 mmHg during systole\n3. Arterial lactate \\>2.0 mmol\u002FL\n4. Echocardiogram with LVEF \\\u003C40% or left ventricular outflow tract velocity time integral (LVOT-VTI) ≤12 cm\n\nExclusion Criteria:\n\n1. Age \\\u003C18 and \\>80 years\n2. Shock duration \\>12 hours\n3. Other causes of shock (hypovolemia, sepsis, pulmonary embolism or anaphylaxis).\n4. Shock due to mechanical complication of AMI\n5. Witnessed out-of-hospital cardiac arrest (OHCA) with chest compression \\>10 min in total (cardiac arrest occurring in ambulance or after hospital arrival is NOT an exclusion criterion and witnessed OHCA with duration of chest compression \\\u003C10 min are also eligible)\n6. After 390 included patients with OHCA, any OHCA will be an exclusion criterion\n7. Any unwitnessed OHCA\n8. Refractory cardiac arrest with ongoing chest compression\n9. Evidence of severe right ventricular failure\n10. Severe aorta valve regurgitation\u002Fstenosis\n11. Severe peripheral arterial obstructive disease precluding mAFP placement\n12. Abnormalities of the aorta precluding mAFP device placement\n13. Presence of a mechanical aortic valve prosthesis\n14. Left ventricular thrombus\n15. Infective endocarditis\n16. Life expectancy \\\u003C1 year due to comorbidities\n17. Mental disorder or language barrier that preclude informed consent\n18. Known pregnancy","80 Years",{"count":59,"type":22},780,[61],"NA","The goal of this clinical trial is to learn which treatment strategies improve survival in adult patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS).\n\nThe main questions it aims to answer are:\n\n* Does the immediate use of a left-sided microaxial flow pump (Impella) after percutaneous coronary intervention (PCI) improve survival compared to initial medical therapy alone?\n* Does protocol-based hemodynamic monitoring and optimization using a pulmonary artery catheter (PAC) improve survival compared to conventional intensive care monitoring?\n\nResearchers will compare four treatment combinations to see if mechanical circulatory support and\u002For advanced hemodynamic monitoring reduce mortality in AMI-CS patients:\n\n* Microaxial flow pump + pulmonary artery catheter\n* Microaxial flow pump + conventional monitoring\n* Medical therapy alone + pulmonary artery catheter\n* Medical therapy alone + conventional monitoring\n\nParticipants will:\n\n* Undergo immediate coronary angiography and PCI upon hospital admission Be randomly assigned to one of four treatment groups\n* Receive either immediate implantation of a microaxial flow pump or initial medical therapy with vasoactive agents following PCI\n* Be monitored either via pulmonary artery catheter with protocol-based hemodynamic optimization or via conventional intensive care monitoring\n* Be followed up at 30 days, 6 months and 12 monthsafter Randomization, with planned annual follow-up assessments for up to 10 years",[64,28,65],"Cardiogenic Shock","Heart Failure, Acute",[67,68,69,70,71,72,73,74,75,76,77],"2x2 factorial design","Mortality","Intensive care","Percutaneous coronary intervention","Hemodynamic monitoring","Mechanical circulatory support","Impella","Microaxial flow pump","AMI-CS","Acute myocardial infarction","Cardiogenic shock","2026-08-07",{"date":80,"type":40},"2026-08-13",{"date":82,"type":22},"2026-10-01",{"date":84,"type":22},"2037-04",{"name":86,"class":47},"Leipzig Heart Science gGmbH",{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100613576","using-advanced-ct-scans-and-blood-markers-to-better-understand-heart-damage-and-recovery-after-a-heart-attack-100613576","NCT07268391","Using Advanced CT Scans and Blood Markers to Better Understand Heart Damage and Recovery After a Heart Attack","SPEctral CT and miRna In Acute Myocardial Infarction for Comprehensive Adverse Remodeling Evaluation","Inclusion Criteria:\n\n* Adults ≥18 years.\n* First STEMI treated with primary PCI.\n* Left ventricular ejection fraction (LVEF) ≤45% during index hospitalization.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Contraindication to iodinated contrast media.\n* Chronic kidney disease with eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m².\n* Prior myocardial infarction or known cardiomyopathy.\n* Contraindication to CT or MRI imaging.\n* Life expectancy \\\u003C1 year due to non-cardiac conditions.",{"count":95,"type":22},95,[61],"Acute myocardial infarction with ST-segment elevation (STEMI) remains a leading cause of morbidity and mortality worldwide. Although advances in reperfusion therapy have reduced early mortality, many patients later develop adverse ventricular remodeling (AVR), which increases the risk of heart failure and cardiovascular death. Current imaging methods, such as echocardiography and cardiac magnetic resonance (CMR), provide valuable prognostic information but have limitations in availability, cost, and their ability to predict AVR early and individually.\n\nSpectral computed tomography (CT) is an emerging imaging technique that can characterize myocardial tissue, quantify infarct size, assess microvascular obstruction, and detect complications, with lower contrast and radiation requirements compared to conventional CT. In parallel, circulating microRNAs (miRNAs) have been identified as stable and non-invasive biomarkers that reflect key biological processes in post-infarction remodeling. Several miRNAs are linked to fibrosis, apoptosis, and ventricular remodeling, suggesting their potential to complement imaging findings in risk prediction.\n\nThis study proposes a multicenter, prospective cohort of patients with STEMI and reduced left ventricular function to evaluate whether combining spectral CT tissue characterization with serum miRNA profiling can improve early prediction of AVR. The main objective is to generate and validate a multiparametric prognostic model integrating imaging and molecular biomarkers to identify high-risk patients who may benefit from closer monitoring and tailored therapeutic strategies.",[28],[100,101,102,103,104],"magnetic resonance","miRNA","myocardial infarction","adverse ventricular remodeling","spectral computed tomography","RECRUITING",{"date":107,"type":40},"2026-08-11",{"date":109,"type":40},"2025-09-15",{"date":111,"type":22},"2028-12",{"name":113,"class":47},"Instituto de Investigación Biomédica de Salamanca",4,{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":145,"leadSponsor":147,"locationsCount":48},"100650523","phase-2-timing-of-empagliflozin-in-primary-pci-pre-reperfusion-versus-post-reperfusion-versus-placebo-in-south-asian-stemi-patients-100650523","NCT07749014","Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients","TEMPO-STEMI","Inclusion Criteria:\n\n* Age 18-75 years at presentation.\n* South Asian ethnicity (Pakistani, Indian, Bangladeshi, Sri Lankan, or Nepali origin).\n* First STEMI: ST-elevation ≥1 mm in ≥2 contiguous limb leads, or ≥2 mm in ≥2 contiguous precordial leads, or new LBBB with consistent presentation.\n* Symptom onset to hospital arrival ≤12 hours.\n* Scheduled for primary PCI with intent to perform balloon inflation and stenting.\n* eGFR ≥45 mL\u002Fmin\u002F1.73m² (CKD-EPI) from point-of-care creatinine at presentation.\n* Able to take oral medication (or crushed tablet with water), swallowing ability confirmed by treating nurse.\n* Written informed consent from patient or legally authorised representative\n\nExclusion Criteria:\n\n* Cardiogenic shock at presentation (Killip IV: SBP \\\u003C90 mmHg despite volume, requiring vasopressors, IABP, or mechanical circulatory support).\n* Type 1 diabetes mellitus.\n* SGLT2 inhibitor use within 3 months of presentation.\n* Active urinary tract infection or genital mycotic infection.\n* eGFR \\\u003C45 mL\u002Fmin\u002F1.73m² at presentation.\n* Severe hepatic impairment (Child-Pugh Class C).\n* Known hypersensitivity to empagliflozin or any SGLT2 inhibitor.\n* History of diabetic ketoacidosis (euglycaemic or classical) at any time.\n* Pregnancy, breastfeeding, or refusal of contraception (women of childbearing potential).\n* Prior myocardial infarction or prior coronary revascularisation.\n* Left main culprit artery as the infarct-related vessel.\n* Rescue PCI after fibrinolysis in the current presentation.\n* Severe multivessel disease with anticipated need for urgent CABG within 48 hours.\n* Cardiac arrest with coma (GCS \\\u003C8) at presentation consent not obtainable and metabolic state unpredictable.\n* Significant metabolic abnormality precluding oral drug: severe vomiting, nil-by-mouth status, or frank dehydration with SBP \\\u003C100 mmHg on arrival.\n* Concurrent participation in another interventional clinical trial.\n* Life expectancy \\\u003C6 months from a non-cardiac cause.\n* Expected inability to attend the 90-day follow-up visit.","75 Years",{"count":124,"type":22},480,[25],"The goal of this clinical trial is to learn if giving the drug empagliflozin before versus after a heart procedure called primary PCI (percutaneous coronary intervention) affects how much heart muscle is damaged during a heart attack. Primary PCI is a procedure that opens blocked heart arteries using a small balloon and stent. While this procedure saves lives, it can also cause extra injury to the heart muscle when blood flow returns. Researchers want to know if empagliflozin given before the procedure can protect the heart better than giving it after the procedure.\n\nThe main questions this trial aims to answer are:\n\nDoes giving empagliflozin before the PCI procedure reduce heart muscle injury more than a placebo (a look-alike pill with no active drug)?\n\nDoes giving empagliflozin before PCI protect the heart better than giving it after PCI?\n\nDoes empagliflozin given after PCI reduce heart muscle injury compared with a placebo?\n\nResearchers will compare three groups of participants to see if the timing of empagliflozin matters:\n\nGroup A receives empagliflozin before the PCI procedure\n\nGroup B receives empagliflozin after the PCI procedure\n\nGroup C receives a placebo at both times\n\nAll three groups will continue taking their assigned study pills for 90 days.\n\nParticipants in this study are adults aged 18 to 75 from South Asian backgrounds (Pakistani, Indian, Bangladeshi, Sri Lankan, or Nepali) who are having their first heart attack and are scheduled for the PCI procedure within 12 hours of their symptoms starting.\n\nParticipants will:\n\nTake a single loading dose of the study pill or placebo right before the PCI procedure\n\nTake a single loading dose of the study pill or placebo within 2 hours after the PCI procedure\n\nContinue taking the study pill or placebo once daily for 90 days\n\nHave blood samples taken 6 times over 48 hours to measure heart muscle injury\n\nHave heart function tests at Day 3, Day 30, and Day 90 (echocardiograms, which are ultrasound pictures of the heart)\n\nHave a special heart scan (CMR) between Day 3 and Day 5 for some participants to get detailed pictures of the heart muscle\n\nComplete 90 days of follow-up with clinic visits and tests\n\nResearchers will measure heart muscle injury using a blood test called high-sensitivity troponin. This test measures a protein that is released when heart muscle is damaged. The total amount of this protein released over 48 hours will tell researchers how much heart muscle was injured.",[128,28,129],"ST-elevation Myocardial Infarction (STEMI)","Coronary Artery Disease",[131,132,133,134,135,136,137,138,139,140],"Empagliflozin","SGLT2 Inhibitor","ST-elevation myocardial infarction","Primary Percutaneous Coronary Intervention","Primary PCI","Ischemia-Reperfusion Injury","Myocardial Infarction","Troponin I","Cardioprotection","South Asian Population","2026-07-31",{"date":143,"type":40},"2026-08-06",{"date":42,"type":22},{"date":146,"type":22},"2027-09-30",{"name":148,"class":47},"Rehman Medical Institute - RMI",{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":167,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100650043","bridge-trial-embedding-consumer-grade-mhealth-technologies-into-cardiac-rehabilitation-100650043","NCT07741396","BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac Rehabilitation","BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac Rehabilitation as a Model for Chronic Disease Management","BRIDGE","Inclusion Criteria:\n\n1. Adults aged 18 years or older.\n2. Enrolled in or referred to Phase II Center-based Cardiac Rehabilitation Program.\n3. Have a qualifying cardiovascular diagnosis or event that meets standard eligibility for Phase II Center-based Cardiac Rehabilitation, such as:\n\n   * Acute myocardial infarction\n   * Percutaneous coronary intervention\n   * Coronary artery bypass graft surgery\n   * Chronic heart failure with reduced ejection fraction\n   * Heart valve repair or replacement\n   * Stable angina\n4. Able to ambulate and participate in exercise testing and training as required by the CR program\n5. Ability to speak and read in English\n6. Willing and able to provide informed consent.\n7. Willing to use study-related devices\u002Fapps and complete study assessments.\n\nExclusion Criteria:\n\n1. Not enrolled in or not planning to participate in Phase II Center-based Cardiac Rehabilitation Program.\n2. Presence of a medical, cognitive, psychiatric, or physical condition that, in the opinion of the investigators or CR team, would preclude safe participation in the study or adherence to study procedures.\n3. Severe cognitive impairment or active psychiatric illness that would interfere with informed consent or study participation.\n4. Terminal illness or other serious medical condition that in the judgement of the treating clinician or investigator would likely preclude completion of the study follow-up period. .\n5. Current hospice enrollment or residence in a long-term care facility that would preclude participation in the intervention or completion of study follow-up procedures.\n6. Currently participating in another behavioral or digital health intervention trial that could confound study outcomes.\n7. Inability or unwillingness to use the required mobile devices, applications, or monitoring equipment, if applicable.",{"count":158,"type":22},30,[61],"The purpose of the BRIDGE study is to learn whether supplementing traditional center-based cardiac rehabilitation (CBCR) with a mobile health technology intervention can help patients monitor their health, stay engaged in healthy lifestyle behaviors, better manage cardiovascular risk factors, and improve overall health outcomes.\n\nCardiac rehabilitation is an evidence-based outpatient program designed to help people recover from heart-related conditions through supervised exercise, education, counseling, and support for healthy lifestyle changes. Although cardiac rehabilitation is highly recommended and beneficial, many patients do not receive the full benefits of the program. Some patients attend fewer sessions than recommended, and many find it difficult to maintain healthy habits outside of the clinic, such as regular physical activity, heart-healthy eating, taking medications as prescribed, monitoring blood pressure, and managing weight.\n\nThis study will test whether combining CBCR with mobile health tools may improve participation and support healthy behaviors at home. Mobile health tools include mobile phone applications, connected devices such as a weight scale, blood pressure monitor, and activity tracker, as well as personalized text messages designed to encourage and support healthy self-care.\n\nThis study will help determine whether these mobile health tools can make cardiac rehabilitation more effective and help patients maintain healthy behaviors beyond the clinic setting.",[28,162,163,164,165,166],"Percutaneous Coronary Intervention (PCI)","Coronary Artery Bypass Graft Surgery (CABG)","Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)","Heart Valve Repair or Replacement","Stable Angina Pectoris",[168,169,170,171],"cardiac rehabilitation","mHealth","digital tool","consumer-grade technology","2026-07-29",{"date":174,"type":40},"2026-08-03",{"date":42,"type":22},{"date":177,"type":22},"2027-07-30",{"name":179,"class":47},"University of Illinois at Chicago",{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":190,"phases":4,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":48},"100646973","early-ga-68-fapi-petmr-after-acute-myocardial-infarction-100646973","NCT07684924","Early Ga-68 FAPI PET\u002FMR After Acute Myocardial Infarction","Early Ga-68 FAPI PET\u002FMR for Assessment of Left Ventricular Remodeling After Acute Myocardial Infarction: A Prospective Single-Center Observational Study","REMODEL-FAPI","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosis of acute myocardial infarction according to current guideline criteria.\n* Successful coronary revascularization when clinically indicated.\n* Ability to undergo FAPI PET\u002FMR.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Contraindications to MRI (e.g., non-MR-compatible implanted devices, severe claustrophobia).\n* Pregnancy or breastfeeding.\n* Severe renal impairment precluding gadolinium administration (if contrast-enhanced MR is performed).\n* Inability to provide informed consent.\n* Any condition considered by the investigator to interfere with study participation.","90 Years",{"count":7,"type":22},"OBSERVATIONAL","Acute myocardial infarction (AMI) initiates a complex myocardial repair process involving inflammation, fibroblast activation, and extracellular matrix remodeling, which may ultimately lead to adverse left ventricular remodeling and impaired cardiac function. Fibroblast activation protein (FAP)-targeted positron emission tomography (PET) enables noninvasive visualization of activated fibroblasts and may provide an early imaging biomarker of myocardial remodeling. This prospective single-center observational study aims to evaluate myocardial fibroblast activation using Ga-68 FAPI PET\u002FMR performed approximately 10 ± 2 days after AMI and to investigate its association with subsequent left ventricular remodeling. Serial cardiac magnetic resonance (CMR) examinations will be performed at 3 and 6 months to assess changes in ventricular function and remodeling. The study will investigate whether early myocardial FAPI uptake is associated with subsequent structural and functional changes detected by CMR and evaluate the potential role of Ga-68 FAPI PET\u002FMR as an imaging biomarker for post-infarction remodeling.",[28],[194,195,196,197,198,199],"Ga-68 FAPI","FAPI PET\u002FMR","Cardiac PET","Left Ventricular Remodeling","Cardiac Magnetic Resonance","Fibroblast Activation Protein","2026-07-24",{"date":202,"type":40},"2026-07-27",{"date":204,"type":40},"2026-07-01",{"date":206,"type":22},"2028-06-29",{"name":208,"class":47},"Ankara University",{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":18,"minAge":216,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":234},"100615539","magenta-elevate-clinical-feasibility-study-in-cardiogenic-shock-100615539","NCT07293923","Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock","Clinical Feasibility Study of the Magenta Elevate™ Percutaneous Left Ventricular Assist Device (pLVAD) System in Patients With Cardiogenic Shock","Inclusion Criteria:\n\n* Cardiogenic shock of less than 24 hours duration.\n* Left ventricular ejection fraction \\\u003C 45% and \\> 15%, as determined by echocardiography on the day of inclusion.\n* No more than mild right ventricular dysfunction, as determined by echocardiography on the day of inclusion.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Other causes of shock: hypovolemia, sepsis (any active systemic infection including acute myocarditis), pulmonary embolism or anaphylaxis.\n* Patient with oxygen saturation \\\u003C 90% (pulse oximeter\u002Farterial) at the planned time of device placement (uncorrected by oxygen supplementation or intubation).\n* Sustained VT (at the time of the enrollment).\n* Significant right heart failure\u002Fright ventricular dysfunction.\n* Awake patient who is unable to remain in a stable recumbent position due to restlessness or lack of cooperation for other reasons.\n* Hypertrophic obstructive cardiomyopathy.\n* Left ventricular thrombus.\n* Subjects with a placed IABP.\n* Mitral and\u002For aortic valve prothesis, or more than mild native mitral or aortic valve stenosis.\n* Aortic valve insufficiency ≥ 2+ (on a 4-grade scale).\n* Mechanical complication of myocardial infarction (e.g., ventricular septal rupture, papillary muscle rupture) or evidence of uncorrected Ventricular Septal Defect or Atrial Septal Defect (VSD\u002FASD).\n* Brain damage (e.g., anoxic) or suspected brain damage.\n* Stroke or transient ischemic attack within the past 3 months.\n* Uncorrectable abnormal coagulation parameters (defined as platelet count \\\u003C 100,000 or INR \\> 2.0 or fibrinogen \\\u003C 1.5 g\u002FL) or active uncontrolled bleeding.\n* Allergy, sensitivity or intolerance to heparin, aspirin, Adenosine Diphosphate (ADP) receptor blockers, or contrast media, including known heparin-induced thrombocytopenia.\n* Known allergy, sensitivity or intolerance to nickel.\n* Known or suspected severe lung disease.\n* Evidence of any vascular disease that would preclude placement of the device (e.g., severely calcified and stenosed ilio-femoral vessels).\n* Aortic pathology, such as aortic aneurysms, extreme tortuosity, or calcifications that could pose an undue additional risk to the placement of a pLVAD device.\n* Any known or suspected disorder causing fragility of blood cells or hemolysis.\n* Subject participation in another investigational drug or device trial (post-market registries may be approved by Magenta Medical).\n* Life expectancy \\\u003C 1 year due to comorbidities.","40 Years","89 Years",{"count":219,"type":22},10,[61],"The Elevate™ CS Clinical Feasibility Study is designed to evaluate the initial safety, effectiveness, and device performance of the Magenta Elevate™ System in patients with cardiogenic shock due to isolated or predominant left ventricular failure.",[64,223,28],"Heart Failure","2026-07-15",{"date":226,"type":40},"2026-07-16",{"date":228,"type":40},"2025-11-05",{"date":230,"type":22},"2028-02-28",{"name":232,"class":233},"Magenta Medical Ltd.","INDUSTRY",8,{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":122,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":249,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":263},"100636587","non-stenting-treatment-strategy-for-acute-myocardial-infarction-with-non-severe-stenosiserosion-iv-100636587","NCT07567625","Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)","Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis: a Prospective, Multicenter, Open-label, Non-inferiority, Randomised Controlled Trial(EROSION IV)","Inclusion Criteria:\n\n1. Male or female patients aged ≥18 years and ≤75 years;\n2. Diagnosis of type 1 AMI, including STEMI (onset \\\u003C24 hours or 7-14 days) or NSTEMI;\n3. After coronary angiography (CAG) ± thrombus aspiration, TIMI flow in the culprit vessel is restored to grade 3 and maintained for at least 5 minutes, with diameter stenosis (DS) \\\u003C70% at the culprit lesion (QCA);\n4. Reference diameter of the culprit lesion \\>2.5 mm and ≤4.0 mm;\n5. Patients or a legally authorized representative must provide written Informed Consent prior to any study related procedure.\n\nExclusion Criteria:\n\n1.Clinical exclusion criteria:\n\n1. Severe cardiac dysfunction (Killip\u002FNYHA class ≥ 3) or LVEF \\\u003C 30%;\n2. Cardiopulmonary resuscitation (CPR) performed at the onset of AMI;\n3. Persistent hemodynamic or cardiac electrical instability after TIMI flow restoration;\n4. Contraindication to antithrombotic drugs, or concurrent hemorrhagic diseases such as peptic ulcer or coagulation disorders;\n5. Contraindication to contrast;\n6. Severe renal dysfunction \\[defined as eGFR ≤30 ml\u002Fmin\u002F1.73m² or Scr ≥2.0 mg\u002FdL\\] without regular dialysis (patients with chronic renal insufficiency on regular dialysis may be considered for enrollment);\n7. Active liver disease, defined as known infectious, neoplastic, or metabolic liver lesions, with ALT and AST \\>3× upper limit of normal (ULN);\n8. Previous history of CABG or PCI for the culprit lesion;\n9. Patients with other concurrent severe diseases and an expected life expectancy of \\\u003C1 year;\n10. Pregnant or lactating women. Women of childbearing potential must use effective contraceptive measures during the study treatment period;\n11. Inability to comply with the study protocol or other conditions deemed unsuitable for study participation by the investigator.\n\n2.Imaging exclusion criteria:\n\n1. Non-culprit lesion with DS ≥70% or planned revascularization;\n2. Left main coronary artery lesion with DS ≥50%;\n3. Culprit lesion is a true bifurcation lesion requiring a two-stent strategy;\n4. Long lesion (planned stent length \\>60 mm);\n5. Culprit lesion with dissection, false lumen, or other conditions necessitating stent implantation;\n6. Target lesion has undergone pre-treatment (such as balloon dilation, rotational atherectomy, etc.).\n\n3.Functional sub study:\n\n1. Individuals who are allergic to adenosine triphosphate (ATP) or any component in its preparations;\n2. Second and third degree atrioventricular block, sick sinus syndrome (without artificial pacemaker protectors);\n3. Patients with bronchial asthma.",{"count":243,"type":22},2000,[61],"This study is a prospective, multicenter, open-label, non-inferiority, randomized controlled trial. A total of 2,000 patients with STEMI (\\\u003C24 hours or 7-14 days) or NSTEMI will be recruited from at least 20 centers in China. Eligible patients must have residual DS \\\u003C 70% at the culprit lesion assessed by QCA, with optional thrombus aspiration, and TIMI flow of grade 3. Patients will be randomly assigned in a 1:1 ratio to the experimental group or the control group. The planned enrollment period is 36 months, and all patients will be followed up for at least 12 months after randomization, with continued follow-up until the end of the study. The primary outcome is the first occurrence of TLF after randomization, defined as the composite of cardiovascular death, target vessel myocardial infarction, ischemia-driven target lesion revascularization. The study aims to verify whether guideline-recommended standard medical therapy is non-inferior to DES implantation combined with guideline-recommended standard medical therapy in AMI patients with non-severe coronary artery stenosis.\n\nA total of 120 participants (60 in the experimental group and 60 in the control group) enrolled at the Second Affiliated Hospital of Harbin Medical University were included in the functional substudy. Using Abbott Pressure Wire™X pressure wire test functional indicators, and explore the incidence of coronary microvascular dysfunction (CMD) as assessed by the index of microcirculatory resistance (IMR) in two groups, and its impact on the rate of the composite endpoint of all-cause death and heart failure readmission occurring for the first time within 12 months.",[28,247,248],"ST-Segment Elevation Myocardial Infarction(STEMI)","Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)",[250,251,252,253,254],"AMI","DES","TLF","IMR","OCT","2026-07-14",{"date":226,"type":40},{"date":258,"type":40},"2026-07-13",{"date":260,"type":22},"2030-12",{"name":262,"class":47},"Harbin Medical University",48,{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":18,"minAge":271,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":190,"phases":4,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":48},"100647120","prospective-cohort-study-of-aging-in-patients-with-acute-myocardial-infarction-100647120","NCT07705997","Prospective Cohort Study of Aging in Patients With Acute Myocardial Infarction","A Single-Center, Prospective, Observational Registry Cohort Study to Investigate Aging-Related Biomarkers, Prognosis, and Risk Prediction in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* 1\\. Age ≥ 60 years old and meet the above comprehensive aging assessment criteria (i.e., combined with at least one clinical phenotype of aging and abnormal blood aging markers on the basis of advanced age); 2. Acute myocardial infarction occurs for ≥ 3 months; 3. Meet the diagnostic criteria for AMI in accordance with the Fourth Edition General Definition of Myocardial Infarction; 4. The patient or their legal representative signs an informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Newly diagnosed acute myocardial infarction, angina pectoris, stroke or transient ischemic attack within the past 3 months; 2. Serious life-threatening diseases (such as advanced malignant tumors, end-stage kidney disease\u002Fliver disease, severe infections) with an estimated lifespan of less than 1 year; 3. Severe cognitive impairment, mental illness, inability to cooperate in completing follow-up, aging assessment, and related examinations; 4. Unable to complete assessment items such as grip strength, walking speed, and 6-minute walk test due to non cardiac reasons such as physical disabilities and severe bone and joint diseases; 5. Failed to sign the informed consent form.","60 Years",{"count":273,"type":22},600,"This is a single-center, prospective, observational cohort study designed to investigate the association between aging-related characteristics and long-term outcomes in patients with acute myocardial infarction (AMI). Approximately 588 eligible participants will be consecutively enrolled and followed for at least 24 months. Clinical data, aging assessments, laboratory examinations, cardiac imaging, and blood samples will be collected to establish a clinical database and biobank. The study aims to identify aging-related prognostic biomarkers, develop a risk prediction model integrating clinical and aging-related indicators, and improve risk stratification and individualized management for patients with AMI.",[28],"2026-07-10",{"date":224,"type":40},{"date":279,"type":22},"2026-08-01",{"date":281,"type":22},"2030-09-01",{"name":283,"class":47},"The Affiliated Hospital of Hangzhou Normal University",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":48},"100646673","crp-apheresis-in-infarct-related-cardiogenic-shock-100646673","NCT07687017","CRP Apheresis in Infarct-Related Cardiogenic Shock","Selective C-Reactive Protein Apheresis in Cardiogenic Shock Complicating Acute Myocardial Infarction (CRP-SHOCK Trial)","CRP-SHOCK","Inclusion Criteria:\n\n* Cardiogenic shock complicating acute myocardial infarction with planned revascularization by percutaneous coronary intervention (PCI).\n* Cardiogenic shock defined as:\n* Systolic blood pressure \\\u003C90 mmHg for \\>30 minutes or requirement of catecholamine infusion to maintain systolic blood pressure ≥90 mmHg, and\n* Signs of impaired organ perfusion (at least one of the following): Cold, clammy skin and extremities, Altered mental status, Oliguria with urine output \\\u003C30 mL\u002Fhour, Arterial lactate \\>2 mmol\u002FL\n* C-reactive protein (CRP) level ≥7 mg\u002FL at baseline.\n* Age ≥18 years.\n* Informed consent provided by the participant or, if the participant is unable to consent, inclusion after assessment and documentation of the presumed patient's will by two physicians (one independent), with informed consent obtained as soon as possible.\n\nExclusion Criteria:\n\n* Fever (body temperature \\>38°C) or acute infection with fever within the last 14 days.\n* Chronic inflammatory disease.\n* Known history of severe hepatic failure.\n* Chronic kidney disease with creatinine clearance \\\u003C30 mL\u002Fmin\u002F1.73 m² prior to hospital admission.\n* Life expectancy \\\u003C12 months prior to cardiogenic shock.\n* Participation in another interventional clinical trial.\n* Pregnancy.\n* Resuscitation duration \\>30 minutes.\n* Cardiogenic shock due to causes other than acute myocardial infarction.\n* Onset of cardiogenic shock \\>12 hours before randomization.\n* Age \\>80 years.",{"count":293,"type":22},50,[61],"Cardiogenic shock complicating acute myocardial infarction remains associated with high short-term mortality despite guideline-directed therapy. Systemic inflammation, particularly elevated C-reactive protein (CRP), may contribute to ongoing myocardial injury and organ dysfunction.\n\nThe CRP-SHOCK trial is an investigator-initiated, prospective, randomized, open-label, multicenter pilot study evaluating selective CRP apheresis as an adjunct to standard of care in patients with infarct-related cardiogenic shock. Patients are randomized to receive either standard therapy alone or standard therapy plus selective CRP apheresis using the PentraSorb®-CRP system.\n\nThe primary objective is to assess the effect of CRP apheresis on the CLIP score at 66 ± 8 hours after randomization. Secondary objectives include clinical outcomes, inflammatory biomarkers, and safety endpoints.",[64,28],[298,299,300,301,302,76,303,304,305,306],"C-reactive protein","CRP apheresis","Selective CRP apheresis","Inflammation","Infarct-related cardiogenic shock","CLIP score","PentraSorb-CRP","Pilot study","Multicenter study","2026-07-03",{"date":309,"type":40},"2026-07-07",{"date":311,"type":22},"2026-07-20",{"date":313,"type":22},"2027-10-31",{"name":86,"class":47},{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":18,"minAge":323,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":340,"leadSponsor":342,"locationsCount":48},"100628866","phase-3-routine-use-of-potassium-competitive-acid-blocker-vs-guideline-directed-gastrointestinal-protection-strategy-in-acute-myocardial-infarction-100628866","NCT07467213","Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction","Routine Use of Potassium Competitive Acid Blocker Versus Guideline-Directed Gastrointestinal Protection Strategy in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy: A Randomized Trial","PCAB-AMI","Inclusion Criteria:\n\n* Patients aged 19 years or older.\n* Patients diagnosed with acute myocardial infarction (ST-segment elevation myocardial infarction \\[STEMI\\] or non-ST-segment elevation myocardial infarction \\[NSTEMI\\]).\n* Patients who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) or drug-coated balloons (DCB).\n* Patients (or their legal representatives) who understood the study risks and benefits and provided voluntary written informed consent.\n\nExclusion Criteria:\n\n* History of hypersensitivity (e.g., allergic reaction, anaphylactic shock) or contraindication to study drugs (potassium-competitive acid blocker \\[P-CAB\\] or proton pump inhibitor \\[PPI\\]).\n* Presence of active gastrointestinal bleeding.\n* Pregnant or breastfeeding women.\n* Non-cardiac life expectancy of less than 1 year or patients expected to have low compliance (as determined by the investigator's medical judgment).\n* Patients who refuse to participate or are unable to follow the requirements specified in the study protocol.","19 Years",{"count":325,"type":22},5000,[327],"PHASE3","This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).",[28,330],"Gastrointestinal Bleeding",[332,333,334,335],"Percutaneous Coronary Intervention","Dual Antiplatelet Therapy","Potassium Competitive Acid Blocker","Zastaprazan","2026-06-23",{"date":338,"type":40},"2026-06-26",{"date":336,"type":40},{"date":341,"type":22},"2030-12-31",{"name":343,"class":47},"Samsung Medical Center",{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":190,"phases":4,"briefSummary":354,"conditions":355,"keywords":357,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":234},"100632733","ventricular-arrhythmias-in-acute-myocardial-infarction-100632733","NCT07517523","Ventricular Arrhythmias in Acute Myocardial Infarction","Ventricular Arrhythmias in the Acute Phase of Myocardial Infarction: ADVERSE MI Study","ADVERSE-MI","Inclusion Criteria:\n\n* ≥ 18 years\n* Acute myocardial infarction\n* Sustained ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation) at the acute phase of an acute myocardial infarction (before hospital discharge)\n* Between January 1, 2012 and April 14, 2024\n\nExclusion Criteria:\n\n* None",{"count":353,"type":22},500,"Ventricular arrhythmias are a serious complication of myocardial infarction. The aim of this study is to provide reliable data on the management and mortality associated with ventricular arrhythmia in the setting of acute myocardial infarction.",[356,28],"Ventricular Arrhythmia",[358,359,360,361,362,363],"ST-segment elevation myocardial infarction","non-ST-segment elevation myocardial infarction","ventricular fibrillation","ventricular tachycardia","cardiac arrest","implantable cardioverter defibrillator","2026-05-26",{"date":366,"type":40},"2026-05-28",{"date":368,"type":40},"2025-06-20",{"date":370,"type":22},"2027-10-01",{"name":372,"class":47},"Poitiers University Hospital",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":190,"phases":4,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":48},"100637765","machine-learning-for-diagnosis-of-occlusive-mi-in-lbbb-patients-100637765","NCT07620119","Machine Learning for Diagnosis of Occlusive MI in LBBB Patients","Development of a Machine Learning Model for the Diagnosis of Occlusive Myocardial Infarction in the Setting of Left Bundle Branch Block","AI-LBBB","Inclusion Criteria:\n\n* Patients aged 18 years and older who present to the emergency department. Patients presenting with acute ischemic chest pain or clinical ischemia-equivalent symptoms (such as acute dyspnea, unexplained diaphoresis, or syncope).\n\nPatients with a confirmed Left Bundle Branch Block (LBBB) on their initial 12-lead electrocardiogram (ECG), which can be either newly developed or known\u002Fchronic.\n\nPatients who undergo invasive coronary angiography during their index hospital admission.\n\nPatients or their legally authorized representatives who provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients under the age of 18. Pregnant or lactating women. Patients with poor-quality or uninterpretable digital ECG recordings due to severe artifact, missing leads, or technical errors.\n\nPatients who develop cardiopulmonary arrest before an initial diagnostic 12-lead ECG can be obtained in the emergency department.\n\nPatients transferred from another healthcare facility who have already undergone coronary angiography or revascularization.\n\nPatients who decline to participate or refuse to provide written informed consent.",{"count":293,"type":22},"This study investigates a new way to diagnose severe heart attacks in patients who have a specific electrical heart pattern called a Left Bundle Branch Block (LBBB). When patients present to the emergency department with chest pain, doctors routinely perform an electrocardiogram (ECG) to check for a heart attack. However, the presence of an LBBB can alter the heart's electrical signals on the ECG, effectively masking or hiding the typical signs of an ongoing acute coronary occlusion (a completely blocked artery). This making it highly challenging for emergency physicians to make an accurate and rapid diagnosis.\n\nThe primary purpose of this prospective and observational research is to develop and evaluate an artificial intelligence\u002Fmachine learning (ML) model that can analyze digital 12-lead ECG signals to accurately predict a true blocked coronary artery in patients with LBBB. The machine learning model will analyze raw digital ECG waveforms to detect subtle, microscopic patterns that might be missed by the human eye.\n\nTo confirm the accuracy of the model, its predictions will be compared directly with invasive coronary angiography results, which is the gold standard reference method used to visualize blocked vessels. Additionally, the study aims to evaluate if the model can differentiate between a true heart attack caused by a blocked artery (Type 1 MI) and other non-occlusive conditions that cause elevated heart enzymes (Type 2 MI). Ultimately, the investigators intend to determine whether integrating this machine learning tool into emergency care can safely reduce the rate of unnecessary emergency invasive procedures for patients who do not have a true coronary blockage.",[28,384,385,386,137],"Left Bundle Branch Block","Coronary Occlusion\u002FThrombosis","Chest Pain","2026-05-22",{"date":389,"type":40},"2026-06-02",{"date":391,"type":22},"2026-06-01",{"date":393,"type":22},"2027-01-31",{"name":395,"class":47},"Konya City Hospital",{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":122,"enrollmentInfo":403,"targetDuration":4,"studyType":23,"phases":405,"briefSummary":406,"conditions":407,"keywords":412,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":48},"100639639","phase-2-recombinant-human-thymosin-beta-4-for-injectionnl005-for-acute-myocardial-infarction-100639639","NCT07586865","Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase IIc Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Recombinant Human Thymosin Beta 4 Injection (NL005) in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* Willing and able to provide written informed consent (by the participant or legally authorized representative)\n* Aged 18 to 75 years old, any sex\n* Diagnosis of ST-segment elevation myocardial infarction (STEMI) with electrocardiogram (ECG) meeting protocol-specified ST-elevation criteria, and scheduled to undergo primary percutaneous coronary intervention (PCI)\n* OR, regardless of ECG criteria, the participant has a completely or nearly completely blocked (TIMI flow grade 0 or 1) proximal or mid left anterior descending (LAD) coronary artery as the single culprit vessel\n* The blocked LAD artery has no visible collateral blood supply from other coronary arteries (Rentrop grade 0)\n* Total myocardial ischemic time (time from chest pain onset to guidewire passage during PCI) meets one of the following: 1. More than 2 hours and less than 6 hours of ischemic time, with either post-PCI LAD TIMI flow grade of 2 or less, or left ventricular ejection fraction (LVEF) of 50% or lower measured by cardiac ultrasound during PCI hospitalization; 2. Between 6 and 24 hours of ischemic time (inclusive)\n* Males and females of childbearing potential must agree to use adequate contraception (such as hormonal or barrier methods, or abstinence) throughout the study\n\nExclusion Criteria:\n\n* Prior history of acute myocardial infarction, chronic total coronary occlusion, coronary thrombolysis, PCI, or coronary artery bypass graft surgery\n* Diagnosis of severe acute heart failure (Killip class III or higher) or chronic heart failure (NYHA functional class III or higher)\n* Severe, uncontrolled arrhythmia that cannot be corrected\n* Presence of aortic dissection\n* Severe liver or kidney dysfunction\n* History of stroke within the past 6 months\n* Current or past diagnosis of any malignancy\n* Blood pressure that remains at or above 180 mmHg systolic and\u002For 110 mmHg diastolic despite adequate antihypertensive treatment\n* History of clinically significant allergic reaction, especially known allergy to protein or biologic drugs\n* Participation in another clinical study within 3 months before screening\n* Unable to undergo cardiac magnetic resonance (CMR) imaging (e.g., due to implanted metal devices, severe claustrophobia, or other contraindications)\n* Any other condition that the investigator believes makes participation unsuitable (for example, the need for urgent or planned revascularization of non-LAD coronary arteries within 3 months)",{"count":404,"type":22},189,[25],"The goal of this phase IIc clinical trial is to learn if recombinant human thymosin beta 4 injection (NL005) works to treat heart damage in people who have had a serious type of heart attack called ST-segment elevation myocardial infarction (STEMI) and have been treated with emergency percutaneous coronary intervention (PCI, a procedure to open the blocked artery). It will also learn about the safety of NL005. The main questions it aims to answer are:\n\n* Does NL005 lower the size of permanent heart muscle damage measured by cardiac magnetic resonance (CMR) scan 90 days after treatment?\n* What medical problems do participants have when taking NL005?\n\nResearchers will compare two different doses of NL005 to a placebo (a look-alike substance that contains no drug) to see if NL005 works better to reduce heart damage caused by the heart attack.\n\nParticipants will:\n\n* Receive NL005 or placebo through a vein within 4 hours after the PCI procedure, then once a day for 7 days\n* Stay in the hospital for the first week for monitoring, blood draws, and electrocardiograms (heart tracings)\n* Have a CMR scan on Day 6 and Day 90 to measure the size of the heart injury\n* Return to the hospital for checkups on Day 30 and Day 90\n* Be contacted by the study team (by phone or online) 3 times during the first year and come back to the hospital on Day 360 to check long-term recovery",[28,408,409,410,411],"Acute Myocardial Infarction of Anterior Wall","Acute Myocardial Infarction With ST Elevation","Acute Myocardial Infarction of Left Ventricle","Acute Myocardial Infarction With ST Segment Elevation",[250,413,414],"CMR","cardioprotective","2026-05-08",{"date":417,"type":40},"2026-05-14",{"date":419,"type":22},"2026-05-18",{"date":421,"type":22},"2028-05-17",{"name":423,"class":233},"Beijing Northland Biotech. Co., Ltd.",{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":18,"minAge":431,"maxAge":122,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":434,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":48},"100634298","phase-2-effect-of-montelukast-on-inflammatory-markers-and-cardiac-injury-in-patients-with-acute-myocardial-infarction-100634298","NCT07537868","Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction","Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 30-75 years Diagnosed with STEMI within 6 hours of symptom onset Undergoing PCI or thrombolysis Eligible for standard ACS therapy signed Informed consent\n\nExclusion Criteria:\n\n* Chronic use of anti-inflammatory drugs\n* Severe hepatic or renal impairment\n* Hypersensitivity to Montelukast\n* Autoimmune or inflammatory diseases\n* Cardiogenic shock, severe heart failure or structural complications such as papillary muscle rupture\n* Having received cardiopulmonary resuscitation\n* Severe and inadequately controlled hypertension\n* History of myocardial infarction\n* Concomitant active bleeding or visceral hemorrhage\n* Concomitant malignant tumors, lymphomas, leukemias, or other diseases\n* gastrointestinal surgery within the past 4 weeks that may affect the absorption of the investigational drug\n* Family history of psychiatric disorders\n* Pregnancy or lactation\n* Participation in another clinical trial","30 Years",{"count":433,"type":22},80,[25],"This is a randomized controlled clinical trial designed to evaluate the therapeutic effects of Montelukast in patients diagnosed with Acute Myocardial Infarction (AMI). The study aims to investigate whether the administration of Montelukast influences inflammatory markers and the extent of cardiac injury following a heart attack.Participants will be randomly assigned to receive either the active medication or a placebo to provide high-quality evidence regarding the drug's potential cardioprotective and anti-inflammatory properties. The trial is conducted through the Faculty of Pharmacy and Faculty of Medicine at Mansoura University",[28],"2026-05-04",{"date":415,"type":40},{"date":440,"type":40},"2026-04-20",{"date":442,"type":22},"2027-10",{"name":444,"class":47},"October 6 University",{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":23,"phases":455,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":219},"100570664","phase-4-treatment-with-aspirin-alone-versus-aspirin-in-combination-with-fondaparinux-before-early-coronary-assessment-in-patients-with-non-st-elevation-myocardial-infarction-100570664","NCT06710184","Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction","Aspirin Versus Aspirin and Fondaparinux Prior to Early Invasive Strategy in Patients With NSTEMI","FOXY","Inclusion Criteria:\n\n* Diagnosis of NSTEMI verified by:\n\n  * Rise or\u002Fand fall in cardiac troponin (cTN) and\n  * Symptoms of acute ischemia or ECG-changes compatible with acute ischemia.\n* Age above 18 years old\n* Expected remaining lifespan above 1 year\n* Informed consent\n\nExclusion Criteria:\n\n* Treatment with any anticoagulants before enrollment and randomization\n\n  * Including any direct anticoagulant (DOAC), LMWH, UFH or warfarin.\n* Not possible with CAG and PCI within 72 hours\n* Unsuitable for CAG and possible PCI due to poor condition\n* Estimated glomerular filtration rate (eGFR) \\\u003C 20 ml\u002Fmin\u002F1.73m2\n* Known liver disease\n* Active bleeding or high risk of bleeding where treatment with Fondaparinux is contraindicated.\n* Anemia (B-Hemoglobin \\\u003C 6.0 mmol\u002Fl)\n* Pregnancy or breastfeeding\n* Endocarditis\n* Indication for acute CAG before enrollment and randomization:\n\n  * ST-elevation Myocardial Infarction (STEMI)\n  * Patients classified as \"Very High Risk\" according to ESC guidelines, defined as(1):\n\n    * Hemodynamic instability (in need of inotropic support) or cardiogenic shock (DANGER-SHOCK criteria (20)) at time of admission.\n    * Acute heart failure because of presumed acute ischemia\n    * Life-threatening arrhythmias or cardiac arrest\n    * Mechanical complications (such as papillary muscle rupture with acute mitral regurgitation, free wall rupture and interventricular rupture)",{"count":454,"type":22},5076,[456],"PHASE4","The main goal of this study is to compare two treatments in patients with a specific type of heart attack called Non-ST-elevation Myocardial Infarction (NSTEMI). The investigators want to find out whether using aspirin alone is as effective and safer than using aspirin together with a second blood thinner called fondaparinux.\n\nBoth treatments will be given before a scheduled heart procedure called coronary angiography (CAG), which may include balloon dilation and stent placement (PCI) if needed.\n\nThe current guidelines recommend using aspirin in combination with a second blood thinner like fondaparinux before CAG and possible PCI. However, these recommendations are based on studies from the 1990s, a time when invasive procedures were not standard practice for these patients. In contrast, nearly all patients with NSTEMI in Denmark (96%) now undergo CAG within 72 hours. This change in practice raises questions about whether the older studies still provide a valid foundation for today's guidelines.\n\nThe study aims to answer two questions:\n\n1. Is aspirin alone as effective as aspirin combined with fondaparinux before early CAG and possible PCI?\n2. Is aspirin alone safer, with a lower risk of severe bleeding, compared to the combination treatment?\n\nTo answer these questions, the investigators will enroll about 5,000 patients with NSTEMI. Participants will be randomly assigned to receive either aspirin alone or aspirin with fondaparinux. The investigators will monitor them for 30 days to compare outcomes such as death, new heart attacks, the need for urgent CAG before the scheduled, and severe bleeding.",[459,28],"NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)",[33,461,462,463,464,465,466,467,468,469,470,68,34,471,472,473,474],"Non-ST Segment Elevation Myocardial Infarction","Aspirin","Fondaparinux","Anticoagulation","Coronary Angiography","Percutaneus Coronary Intervention","Acute Coronay Syndrome","Early Invasive Treatment","Refractory ischemia","Bleeding risk","New Myocardial Infarction","Non-inferiority Trial","Multicenter Study","Antithrombotic","2026-04-28",{"date":437,"type":40},{"date":478,"type":40},"2025-05-01",{"date":480,"type":22},"2029-07-01",{"name":482,"class":47},"University of Aarhus",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":491,"targetDuration":493,"studyType":190,"phases":4,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":502,"locationsCount":504},"100634254","coronary-and-myocardial-evaluation-by-cardiac-ct-for-acute-myocardial-infarction-100634254","NCT07537296","Coronary and Myocardial Evaluation by Cardiac CT for Acute Myocardial Infarction","Multimodal Cardiac CT-Derived High-Risk Coronary and Myocardial Features for Predicting Adverse Outcomes After PCI in Patients With Acute Myocardial Infarction: A Multicenter Prospective Cohort Study","COMET-AMI","Inclusion Criteria:\n\n* Age ≥18 years\n* AMI within the previous 4 weeks, including STEMI or NSTEMI\n* PCI performed for ACS culprit lesion according to current guidelines\n* Hemodynamically stable\n* Willingness to undergo multimodal cardiac CT within 7 days after PCI\n* Willingness to participate in telephone follow-up\n\nExclusion Criteria:\n\n* Contraindications to cardiac CT (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m² or iodine contrast allergy)\n* Previous coronary artery bypass graft surgery (CABG)\n* History of heart failure or previous myocardial infarction\n* Severe arrhythmia or structural heart disease\n* Poor image quality or missing CT data\n* Expected survival \\\u003C6 months",{"count":492,"type":22},1000,"5 Years","Acute myocardial infarction (AMI) remains a major cause of mortality and morbidity worldwide. Although percutaneous coronary intervention (PCI) combined with guideline-directed medical therapy has substantially improved survival, many patients continue to experience adverse cardiovascular events after revascularization, including recurrent ischemic events, heart failure, and malignant arrhythmias. Therefore, accurate risk stratification after PCI is essential for optimizing clinical management and improving long-term outcomes. However, currently available risk prediction tools are limited by suboptimal predictive performance or restricted clinical accessibility.\n\nCardiac imaging plays a central role in post-AMI evaluation. Echocardiography is routinely recommended after PCI to assess cardiac structure and function and to exclude early mechanical complications. Nevertheless, its ability to predict subsequent ventricular remodeling and long-term clinical outcomes is limited. Cardiac magnetic resonance imaging (CMR) is considered the reference standard for myocardial tissue characterization and provides important prognostic markers such as infarct size, microvascular obstruction, and intramyocardial hemorrhage. However, the routine use of CMR in patients with AMI is constrained by limited availability, high cost, and relatively long examination time. In addition, CMR does not directly evaluate coronary artery anatomy or plaque characteristics, which are important determinants of recurrent ischemic events.\n\nRecent advances in cardiac computed tomography (CT) have enabled comprehensive assessment of coronary artery disease. Beyond evaluating coronary stenosis, coronary CT angiography can identify high-risk plaque features associated with plaque vulnerability. Furthermore, emerging CT-based techniques allow simultaneous assessment of coronary physiology, perivascular inflammation, myocardial structure and function, and myocardial tissue characteristics. CT-derived fractional flow reserve (CT-FFR) enables noninvasive functional assessment of coronary lesions, while the fat attenuation index (FAI) reflects pericoronary inflammatory activity. In addition, delayed iodine enhancement and dual-energy CT techniques allow evaluation of myocardial injury and fibrosis, and CT-derived extracellular volume fraction (ECV) provides quantitative assessment of myocardial fibrosis. These advances suggest that multimodal cardiac CT may provide an integrated imaging approach for comprehensive risk assessment after AMI.\n\nThe COMET-AMI study (Coronary and Myocardial Evaluation by Multimodal Cardiac CT in Acute Myocardial Infarction) is a prospective, multicenter cohort study designed to evaluate the prognostic value of multimodal cardiac CT in patients with AMI after PCI. A total of 1,000 patients with AMI undergoing successful PCI will be prospectively enrolled. All participants will undergo multimodal cardiac CT within 7 days after PCI to assess coronary plaque characteristics, coronary physiology, pericoronary adipose tissue inflammation, cardiac structure and function, and myocardial tissue features. A subset of participants will also undergo cardiac magnetic resonance imaging for validation of CT-derived myocardial tissue parameters.\n\nComprehensive clinical information, including demographic characteristics, cardiovascular risk factors, medication history, laboratory biomarkers, and procedural data, will be collected. Quantitative and qualitative analyses of coronary plaques will be performed using dedicated software to assess plaque burden, plaque composition, remodeling characteristics, and high-risk plaque features. Additional CT-derived parameters such as CT-FFR, myocardial strain, pericoronary fat attenuation index, and extracellular volume fraction will also be analyzed.\n\nParticipants will be followed longitudinally through outpatient visits, telephone interviews, and electronic medical record review for up to five years after PCI. The primary outcomes include composite thrombotic events (cardiac death, recurrent myocardial infarction, and urgent or clinically driven revascularization). Secondary outcomes include heart failure and major arrhythmic events such as new-onset heart failure, sustained ventricular arrhythmia, implantable cardioverter-defibrillator implantation, sudden cardiac death, or resuscitated cardiac arrest. All clinical events will be independently adjudicated by a blinded clinical events committee.\n\nUsing multimodal cardiac CT-derived imaging biomarkers in combination with clinical and laboratory data, machine learning-based predictive models will be developed to identify key determinants of adverse outcomes after PCI in patients with AMI. The results of this study may provide a novel imaging-based risk stratification strategy and facilitate personalized management for patients with AMI after PCI.",[28],"2026-04-12",{"date":498,"type":40},"2026-04-17",{"date":500,"type":40},"2026-01-01",{"date":341,"type":22},{"name":503,"class":47},"Nanjing First Hospital, Nanjing Medical University",2,{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":23,"phases":515,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":527},"100525172","phase-3-artemis---a-research-study-to-look-at-how-ziltivekimab-works-compared-to-placebo-in-people-with-a-heart-attack-100525172","NCT06118281","ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack","ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction","ARTEMIS","Key inclusion:\n\n* Age 18 years or above at the time of signing the informed consent.\n* Hospitalisation for acute myocardial infarction with evidence of type 1 myocardial infarction (MI) by invasive angiography performed at site with percutaneous coronary intervention (PCI) capabilities.\n* ST-segment elevation myocardial infarction (STEMI) with all the following: a) Relevant onset of symptoms suggestive of cardiac ischaemia within 12 hours before hospitalisation, at the investigator's discretion.\n\n  b) Electrocardiogram (ECG)-changes (in the absence of left ventricular hypertrophy or left bundle branch block): ST-segment elevation at the J point in at least two contiguous leads greater than or equal 0.25 (millivolt) mV in men less than 40 years, greater than or equal 0.2 mV in men greater than or equal 40 years, or greater than or equal 0.15 mV in women in leads V2-V3; and\u002For greater than or equal 0.1 mV in all other leads.\n\nOR\n\n* Non-ST-segment myocardial infarction with all the following: a) Relevant onset of symptoms suggestive of cardiac ischaemia within 24 hours before hospitalisation, at the investigator's discretion. b) Rise and\u002For fall in car-diac troponin I or T with at least one value above the 99th percentile upper reference limit.\n* Possibility for both randomisation and administration of the loading dose of study intervention as early as possible after invasive procedure, and latest within 36 hours of hospitalisation (time 0) for STEMI, and latest within 72 hours of hospitalisation (time 0) for NSTEMI.\n* Presence of at least one of the following criteria confirmed based on the participant's medical records and\u002For medical history interview: a) Any prior MI. b) Prior coronary revascularisation. c) Diabetes mellitus treated with ongoing glucose-lowering agent(s). d)Known chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) greater than or equal to 15 and less than 60 milliliter per minute per 1.73 square meter (mL\u002Fmin\u002F1.73 m\\^2). e) Prior ischaemic stroke. f) Known carotid disease or peripheral artery disease in the lower extremities. g) Multivessel coronary artery disease (current\u002Fprior). h) For STEMI patients only: anterior MI at index acute myocardial infarction (AMI)\n\nKey exclusion:\n\n* Use of fibrinolytic therapy for treatment of the current AMI.\n* Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV.\n* Ongoing haemodynamic instability defined as any of the following: a) Killip Class III or IV. b) Sustained and\u002For symptomatic hypotension (systolic blood pressure less than 90 millimeters of mercury (mmHg)).\n* Severe kidney impairment defined as any of the following: a) eGFR less than 15 mililitre per minute per 1.73 m\\^2. b) Chronic haemodialysis or peritoneal dialysis.\n* Known alanine aminotransferase (ALT) greater than 8 x upper limit of normal (reference range) (ULN).\n* Severe hepatic disease defined as at least one of the following: a) Previously known or current hepatic encephalopathy (clinical evaluation). b) Previously known or current ascites (clinical eval-uation). c) Jaundice (clinical evaluation). d) Previous oesophageal\u002Fgastric variceal bleeding. c) Known hepatic cirrhosis.\n* Major cardiac surgical (including but not restricted to coronary artery bypass graft surgery (CABG)), non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days or any major surgical procedure planned at the time of randomisation or as treatment for the current AMI (CABG). Deferred (staged)percutaneous coronary intervention for a non-culprit vessel identified during the current AMI is allowed.\n* Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.\n* Known (acute or chronic) hepatitis B or hepatitis C.\n* History or evidence of untreated latent tuberculosis (TB) such as (but not limited to): a) History of a positive TB test or chest X-ray compatible with latent TB; and TB treatment initiated less than 28 days prior to randomisation. b) Participants with TB risk factors but unwilling to undergo TB treatment if confirmed positive for latent TB based on central laboratory test at baseline (visit 2).",{"count":514,"type":22},10000,[327],"The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.",[518,28],"Cardiovascular Risk",{"date":520,"type":40},"2026-04-14",{"date":522,"type":40},"2024-06-25",{"date":524,"type":22},"2026-12-14",{"name":526,"class":233},"Novo Nordisk A\u002FS",970,{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":534,"enrollmentInfo":535,"targetDuration":4,"studyType":190,"phases":4,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":4},"100631150","construction-and-analysis-of-a-risk-prediction-model-for-acute-myocardial-infarction-based-on-spatiotemporal-heterogeneous-data-100631150","NCT07496931","Construction and Analysis of a Risk Prediction Model for Acute Myocardial Infarction Based on Spatiotemporal Heterogeneous Data","Inclusion Criteria:\n\n1. High-risk population for acute myocardial infarction, previously confirmed by cardiac imaging to have coronary artery disease and at least one of the following risk factors:\n\n   * Multivessel coronary artery disease (defined as ≥50% stenosis in at least 2 coronary artery regions, including the left main coronary artery)\n   * Previous myocardial infarction\n   * Patients with diabetes currently undergoing glucose-lowering treatment\n   * Chronic kidney disease (CKD) defined as an estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m² with a known history of chronic kidney disease or biomarkers indicating chronic kidney damage\n   * Peripheral artery disease, defined as any of the following: ankle-brachial index \\\u003C0.85; \\>50% stenosis in lower limb arteries confirmed by angiography (invasive or non-invasive) or duplex ultrasound; limb amputation, peripheral artery bypass, or vascular surgery (such as angioplasty or endarterectomy) secondary to ischemia\n2. Age ≥18 years\n3. Ability to understand and comply with the study protocol and sign the informed consent form\n\nExclusion Criteria:\n\n1. Researchers consider diseases or conditions that are not suitable for participation in this study (such as mental illness, significant cognitive impairment, neurodegenerative diseases, advanced malignant tumors) or situations (such as inability to communicate well with researchers in the local language, unwillingness to comply with study procedures\u002Finstructions, inability to understand study-specific training, physically fragile and vulnerable subjects).\n2. Participation in a clinical trial involving drugs or devices within 3 months prior to enrollment.\n3. Women who are pregnant, planning to become pregnant, or breastfeeding.\n4. Known life-threatening diseases with an expected survival of less than 12 months.","85 Years",{"count":536,"type":22},3000,"Acute myocardial infarction (AMI), as the leading cause of death among cardiovascular diseases, has its diagnosis and treatment efficiency directly affecting survival. Although the current diagnosis and treatment system has significantly improved in-hospital outcomes, delays in seeking medical care due to patients' insufficient awareness and out-of-hospital deaths are common, representing the biggest bottleneck in improving diagnostic and treatment capabilities. This study takes intelligent-assisted diagnosis of AMI as the entry point and proposes a technical approach that combines a deep learning algorithm based on 12-lead electrocardiograms with wearable monitoring devices. By utilizing morphological feature extraction and deep learning models, it aims to achieve early identification and warning of AMI. The study plans to build a multi-center AMI long-term follow-up cohort covering the Beijing area based on spatiotemporal heterogeneous data. By integrating and forming a precise high-risk cohort of 3,000 acute myocardial infarction cases, it seeks to construct an AMI risk prediction model that combines deep learning with a retrieval-augmented generative expert system, breaking through bottlenecks in ECG recognition and temporal prediction, enhancing model generalization and transferability. Ultimately, it will support the application of wearable devices, shorten pre-hospital delays, achieve early warning and precise diagnosis of AMI, reduce reinfarction and cardiac-related mortality, and carry significant clinical and public health importance.",[28],"2026-03-23",{"date":541,"type":40},"2026-03-27",{"date":543,"type":22},"2026-03-25",{"date":545,"type":22},"2027-05-31",{"name":547,"class":47},"Beijing Anzhen Hospital",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":555,"enrollmentInfo":556,"targetDuration":4,"studyType":190,"phases":4,"briefSummary":558,"conditions":559,"keywords":562,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":48},"100629214","prospective-lifespan-cohort-of-myocardial-infarction-100629214","NCT07471763","Prospective Lifespan Cohort of Myocardial Infarction","A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System","Inclusion Criteria:\n\nAge 18 to 74 years\n\nDiagnosed with stable angina, unstable angina, or acute myocardial infarction\n\nFor acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized\n\nDiagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction\n\nWilling to participate and able to provide written informed consent\n\nAble to complete baseline assessment, biospecimen collection, and long-term follow-up\n\nExclusion Criteria:\n\nEnd-stage malignant tumor with expected survival of less than 1 year\n\nSevere hepatic or renal dysfunction (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m² or Child-Pugh class C)\n\nActive autoimmune disease or long-term use of immunosuppressive agents\n\nPregnant or breastfeeding women\n\nInability to provide informed consent or severe cognitive impairment\n\nPrevious participation in another clinical study that may conflict with this project\n\nAny other condition considered by the investigators to make participation inappropriate","74 Years",{"count":557,"type":22},6000,"This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management.\n\nThe study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up.\n\nThe primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.",[28,560,561],"Stable Angina","Unstable Angina",[563,564,565,566,567,568,569],"prospective cohort","multi-omics","artificial intelligence","risk prediction","precision medicine","acute myocardial infarction","lifespan cohort","2026-03-22",{"date":543,"type":40},{"date":573,"type":22},"2026-04-10",{"date":575,"type":22},"2031-04-10",{"name":577,"class":47},"Fujian Provincial Hospital",{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":23,"phases":588,"briefSummary":589,"conditions":590,"keywords":592,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":48},"100614183","phase-3-effects-of-ziltivekimab-on-coronary-atherosclerotic-burden-in-patients-with-acute-myocardial-infarction-100614183","NCT07276282","Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction","Effects of Ziltivekimab Versus Placebo on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-infrared Spectroscopy and Optical Coherence Tomography Imaging Study","ZEPHYR","Key Inclusion Criteria:\n\n* Informed consent obtained before any study-related activities.\n* Age 18 years or above at the time of providing informed consent.\n* Acute myocardial infarction, with at least one coronary segment (culprit lesion) treated with PCI.\n* At least two major native coronary arteries each meeting angiographic criteria for intracoronary imaging immediately following the qualifying PCI procedure.\n\nKey Exclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel.\n* Female of childbearing potential.\n* Left-main disease.\n* Three-vessel disease.\n* History of coronary artery bypass surgery.\n* TIMI flow \\\u003C2 of the infarct-related artery after PCI.\n* Unstable clinical status (hemodynamic or electrical instability.\n* Significant coronary calcification or tortuosity deemed to preclude IVUS, NIRS and OCT evaluation.\n* Uncontrolled cardiac arrhythmia.\n* Severe kidney impairment.\n* Active liver disease or hepatic dysfunction.\n* Current use of anti-IL-6 products or anticipated use of such drugs any time during the study.\n* Use of systemic immunosuppressive drugs or disease modifying anti-rheumatic drugs or anticipated chronic use of such drugs any time during the study.\n* Known, or suspicion of, active infection or major hematologic, metabolic, or endocrine dysfunction in the judgment of the Investigator\n* History of recurrent serious infections.\n* Use of preventive systemic antibiotics, systemic antivirals, or systemic antifungals.\n* Known (acute or chronic) hepatitis B or hepatitis C\n* Planned surgery within 12 months from the time of screening.\n* History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, low risk prostate cancer, or carcinoma in situ\u002Fhigh grade prostatic intraepithelial neoplasia (PIN) at the discretion of the investigator.\n* Estimated life expectancy less than 2 years\n* Received a live or attenuated-live vaccine product within 4 weeks of study intervention administration or expected to receive a live or attenuated-live vaccine product during the treatment period.\n* Major cardiac surgical within the past 60 days or any major surgical procedure planned at the time of randomisation or as treatment for the current AMI (CABG).",{"count":587,"type":22},332,[327],"Despite improvements in the treatment, coronary artery disease (CAD) remains one of the leading causes of death worldwide. Around 20% of people who have suffered a heart attack (myocardial infarction) need to be hospitalized again within a year, and 10% experience another heart attack. Despite currently available medication, patients remain at risk of further episodes after a heart attack. Scientists have discovered that inflammation in the body plays a decisive role in the development and narrowing of arterial blockages (atherosclerosis). This study aims to investigate whether a new treatment that reduces inflammation can help improve the arteries of patients with CAD.\n\nThis study will examine whether blocking certain inflammation-related substances with a new medicinal product called ziltivekimab affects the buildup and composition of plaques (fatty deposits) in the coronary arteries. Special imaging diagnostic techniques will be used to look inside the arteries and check whether the treatment helps reduce the narrowing caused by dangerous plaques, which can lead to future heart attacks.\n\nThis is a clinical study in which participants are randomly divided into two groups (randomization): one group will receive the new treatment ziltivekimab and other group will receive a placebo (a harmless substance with no active ingredients). Both groups will continue to receive standard treatment for heart attacks. The study lasts approximately 15 months per participant.\n\nThe full scientific title of the trial is: Effects of ziltivekimab versus placebo on coronary atherosclerosis in patients with acute myocardial infarction. A study with serial multi-vessel imaging obtained using intravascular ultrasound, near-infrared spectroscopy, and optical coherence tomography techniques.",[129,28,591],"Coronary Atherosclerosis of Native Coronary Artery",[593,594,568,595,596],"IL-6 inhibition","atherosclerosis","anti-inflammatory","intracoronary imaging","2026-03-20",{"date":539,"type":40},{"date":600,"type":40},"2025-12-19",{"date":602,"type":22},"2028-12-01",{"name":604,"class":233},"ECRI bv",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":122,"enrollmentInfo":613,"targetDuration":4,"studyType":23,"phases":615,"briefSummary":616,"conditions":617,"keywords":619,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":48},"100613537","iabp-for-mi-vsd-patients-in-scai-shock-stage-b-100613537","NCT07267884","IABP for MI-VSD Patients in SCAI SHOCK Stage B","Evaluation of the Effectiveness and Safety of Intra-Aortic Balloon Pump Insertion in Patients With Ventricular Septal Defect Following Myocardial Infarction During SCAI SHOCK Stage B: A Multicenter, Randomized, Open-Label, Parallel Controlled Study","IABP-VISTAS","Inclusion Criteria:\n\n* Age between 18 and 75 years;\n* Diagnosed with AMI based on clinical manifestations, electrocardiogram, cardiac troponin markers, etc.;\n* Diagnosis of MI-VSD by echocardiography;\n* Patients in stage B according to the SCAI shock stage definition before enrollment, meeting the following conditions: (1) good mental status, (2) warm limbs without cold and clammy feeling, (3) Killip class 2, with the beginning of wet rales at the lung bases, (4) arterial blood lactate ≤ 2mmol\u002FL, (5) normal renal function or mild renal impairment (creatinine increase less than 1.5 times baseline or eGFR decrease ≤ 50%), (6) no use of vasoactive drugs;\n* Obtain informed consent.\n\nExclusion Criteria:\n\n* Age \\> 75 years;\n* Congenital heart disease with ventricular septal defect;\n* Complications such as free wall rupture, papillary muscle dysfunction, etc.;\n* Typical cardiogenic shock (SCAI shock stages C-E) before enrollment, any of the following: (1) altered mental status, (2) cold and clammy skin, (3) Killip class 3 or 4, (4) arterial blood lactate \\> 2mmol\u002FL, (5) severe liver and kidney function impairment, (6) use of vasoactive drugs to maintain blood pressure; or in shock risk period (stage A);\n* Chronic end-stage organ dysfunction that is not expected to be suitable for surgical treatment;\n* Shock caused by other reasons (such as sepsis or hypovolemia);\n* Patients with an expected life span of less than 12 months;\n* Aortic valve insufficiency more than grade II, aortic dissection or aneurysm cannot be ruled out;\n* Difficulty in implanting IABP due to severe peripheral vascular disease or other reasons;\n* Pregnancy and lactation;\n* Refusal to sign the informed consent form, disagreement to insert IABP, or no willingness to proceed with further surgical treatment.",{"count":614,"type":22},100,[61],"Ventricular septal defect (MI-VSD) is a serious mechanical complication of acute myocardial infarction, with an extremely high mortality. Intra-aortic balloon pump (IABP) is still the most easily available mechanical assistive device for clinical management, and it has become a bridge to surgical repair.\n\nIABP-SHOCK II trial is currently the largest randomized controlled trial (RCT) related to the use of IABP among patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS), the trial found that IABP had a negative impact on 30-day, 1-year, and 6-year all-cause mortality. However, the trial included patients with typical cardiogenic shock (shock stages C-E, SCAI definition criteria), most of whom had severely inadequate microcirculatory perfusion, limiting the effectiveness of IABP treatment.\n\nThere is still no clinical study on the usage of IABP in MI-VSD patients with early-stage CS. The main objective of this study is to assess the correlation between the utilization of IABP and 30-day mortality rates among MI-VSD patients with early-stage CS. The investigators will also follow up on the long-term prognosis of these patients. The investigators will enroll multicenter patients with MI-VSD who are at the onset of cardiogenic shock (SCAI SHOCK stage B) to explore the impact of IABP support on the prognosis of these patients.\n\nThis prospective, multicenter, randomized, open-label, parallel-group controlled study will involve 100 participants who are diagnosed with MI-VSD complicated by SCAI SHOCK stage B in about 5 centers. After reviewing the inclusion criteria, participants will be randomized to two groups (Early-CS-IABP group and Control group) in a ratio of 1:1. The primary outcome is all-cause mortality within 30 days after MI-VSD. The investigators will also observe 6-month and 1-year all-cause mortality after MI-VSD.\n\nThe investigators speculated that IABP could significantly improve the clinical outcomes of patients with MI-VSD if it could be used in the early stage of cardiogenic shock.",[28,618],"Ventricular Septal Defects (VSD)",[620,568,621,622],"Intra-aortic balloon pump","ventricular septal defect","cardiogenic shock","2026-03-17",{"date":625,"type":40},"2026-03-19",{"date":627,"type":22},"2026-02-28",{"date":629,"type":22},"2029-10-31",{"name":631,"class":47},"Qilu Hospital of Shandong University",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":23,"phases":642,"briefSummary":643,"conditions":644,"keywords":645,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":234},"100573287","fast-discharge-after-acute-myocardial-infarction-discharge-mi-100573287","NCT06744322","Fast Discharge After Acute Myocardial Infarction Discharge MI","Fast Discharge After Acute Myocardial Infarction Discharge MI - A Randomized Multicenter Non Inferiority Trial","DISCHARGE-MI","Inclusion Criteria:\n\n* Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC\n* Age ≥ 18 years at time of consent\n* Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow\n* Ability to understand and willingness to sign and date written informed consent\n\nExclusion Criteria:\n\n* Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest\u002Fin-hospital cardiac arrest)\n* PCI-related complications (coronary perforation, side branch closure, inability to deliver stent\u002Fballoon, aortic dissection, allergic reaction grade ≥2, stroke\u002Fthromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection\u002Focclusion or emboli)\n* Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (\\\u003C 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- \u002Fthird-degree atrioventricular block) after PCI\n* Ongoing hemodynamic instability (systolic blood pressure \\\u003C90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors)\n* Ongoing respiratory instability defined by Killip class \\>I (rales, pulmonary edema)\n* Ongoing quantitative disorders of consciousness (somnolence, sopor, coma)\n* Acute kidney injury defined by Kidney Disease Improving Global Outcomes (KDIGO) stages 2 and 3\n* Pregnancy\n* Untreated critical non-culprit lesions requiring revascularization during index hospitalization not allowing fast discharge\n* Immobility\u002Flimited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team",{"count":641,"type":22},2070,[61],"To evaluate the hypothesis that a fast discharge strategy (discharge at 24 \\[± 12\\] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (\\>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.",[28],[137,646,647,648,649],"STEMI","NSTEMI","Discharge","Randomized","2026-03-11",{"date":652,"type":40},"2026-03-16",{"date":654,"type":40},"2024-12-01",{"date":656,"type":22},"2029-12-31",{"name":658,"class":47},"Medical University Innsbruck",{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":664,"acronym":665,"eligibilityCriteria":666,"healthyVolunteers":12,"sex":18,"minAge":667,"maxAge":4,"enrollmentInfo":668,"targetDuration":4,"studyType":23,"phases":670,"briefSummary":671,"conditions":672,"keywords":673,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":677,"lastUpdatePostDateStruct":678,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":682,"locationsCount":114},"100603299","phase-2-safety-and-efficacy-of-misaver-cb-cells-for-acute-myocardial-infarction-phase-ii-100603299","NCT07134712","Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II","Safety and Efficacy Study of Intravenous Administration of MiSaver (Umbilical Cord Blood Derived Nucleated Cells) After Acute Myocardial Infarction","SEMIAMI","Inclusion Criteria:\n\n1. Age ≥ 45 years, BMI ≤ 32\n2. Patients diagnosed with acute myocardial infarction by a cardiologist, within 36 hours to 7 days post-diagnosis, and able to complete cell infusion within this period.\n3. Left ventricular ejection fraction (LVEF) ≤ 45%, hemodynamically stable patients who do not require vasopressor support within 24 hours.\n4. Patients with a history of coronary artery disease, who have previously undergone percutaneous coronary intervention or coronary artery bypass graft surgery, may also be included upon evaluation by a cardiologist.\n5. Patients deemed unsuitable for percutaneous coronary intervention or coronary artery bypass graft surgery by a cardiologist.\n6. Must agree to sign the informed consent form.\n7. Subjects must use effective contraception during the study observation period and for 6 months after its conclusion to ensure no pregnancy occurs during the study. (Primarily for women of childbearing potential).\n8. Agree to and comply with the required outpatient visits and examinations during the study observation period.\n\nExclusion Criteria:\n\n1. Age \\\u003C 45 years, BMI \\> 32.\n2. Women who are planning to become pregnant, are pregnant, or are breastfeeding\n3. Immunodeficiency diseases caused by infection , such as Human Immunodeficiency Virus (HIV).\n4. Patients diagnosed as needing coronary artery bypass surgery or potentially requiring coronary revascularization surgery within the next 6 months.\n5. Severe aortic or mitral valve stenosis.\n6. Life-threatening arrhythmias.\n7. Malignant tumors, including all categories and cancer conditions.\n8. Hematologic disorders or other severe organ diseases with an expected survival of less than one year.\n9. Chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²) or patients undergoing dialysis.\n10. Patients with autoimmune diseases or those who have already received immunotherapy.\n11. Patients who have undergone tumor treatment or require immunosuppressive therapy within the last three years.\n12. History of transfusion reactions.\n13. Recipients of bone marrow or organ transplants.\n14. Liver dysfunction (bilirubin \\> 2.5 mg\u002FdL or transaminases \\> 5x the upper limit of normal).\n15. Patients who have previously received growth factors, cytokines, gene therapy, or stem cell therapy.\n16. Subjects participating in more than one clinical trial.\n17. Inability to sign the consent form or comply with outpatient follow-up after infusion therapy.\n18. Patients with a known allergy to this product or its excipients (e.g., dimethyl sulfoxide, cell preservation solution).","45 Years",{"count":669,"type":22},102,[25],"This trial is a Phase II, multicenter clinical study. The purpose of this trial is to evaluate the safety and efficacy of MiSaver, a cellular therapy product, in patients who have experienced an acute myocardial infarction (AMI). Specifically, the study aims to assess the improvement in left ventricular function of the heart following the administration of MiSaver, as well as to determine the safety of using stem cell therapy in these patients.\n\nThis trial will employ a single-blind design (subject-blinded), meaning that the participants will not be aware of whether they are receiving MiSaver or standard treatment, while the researchers will have this information. This design helps ensure transparency and adherence to ethical standards while also providing valuable clinical insights.\n\nBy utilizing randomization, we can enhance the reliability and comparability of the study results. A portion of the participants will receive MiSaver, while the others will undergo standard treatment. This allows for a direct comparison of the two therapeutic approaches to determine their respective efficacy.\n\nThe primary objective of this trial is to evaluate the safety and efficacy of MiSaver, in the treatment of patients with acute myocardial infarction (AMI). To achieve this, we will collect comprehensive participant data, including assessments of cardiac function, records of cardiac events, and quality-of-life surveys. By analyzing these data, we aim to gain a deeper understanding of the benefits and limitations of this treatment approach.",[28],[674,675,676],"heart attack","stem cell","Cardiovascular diseases","2026-03-09",{"date":650,"type":40},{"date":680,"type":22},"2026-03-30",{"date":44,"type":22},{"name":683,"class":233},"HONYA Medical Co Ltd",{"id":685,"slug":686,"hasResults":12,"nctId":687,"briefTitle":688,"officialTitle":689,"acronym":4,"eligibilityCriteria":690,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":691,"enrollmentInfo":692,"targetDuration":4,"studyType":23,"phases":694,"briefSummary":695,"conditions":696,"keywords":697,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":699,"lastUpdatePostDateStruct":700,"startDateStruct":702,"completionDateStruct":703,"leadSponsor":705,"locationsCount":48},"100608934","very-early-pcsk9-inhibition-for-acute-myocardial-infarction-100608934","NCT07208006","Very Early PCSK9 Inhibition for Acute Myocardial Infarction","Impact of PCSK9 Monoclonal Antibody Very Early Administered in Hospital to Reduce Cardiovascular Events in Acute Myocardial Infarction (IMMEDIATE -MI)","Inclusion Criteria\n\n1. Age ≥18 years.\n2. Acute myocardial infarction (AMI) onset within 30 days (first hospitalization with a confirmed diagnosis of STEMI or NSTEMI).\n3. Multivessel coronary artery disease; successful percutaneous coronary intervention (PCI) of the culprit lesion in the infarct-related artery (IRA), including stent implantation and\u002For balloon angioplasty and\u002For thrombus aspiration.\n4. At least one angiographically assessed diameter stenosis ≥50% in a non-infarct-related artery (non-IRA) with a reference vessel diameter ≥2.5 mm.\n5. Able to understand and willing to provide written informed consent, comply with prescribed medical therapy, and complete the required follow-up.\n\nExclusion Criteria\n\n1. Cardiogenic shock or severe heart failure (Killip class IV).\n2. Serum creatinine \\>150 μmol\u002FL or glomerular filtration rate (GFR) \\\u003C45 mL\u002Fmin\u002F1.73 m² calculated by the Cockcroft-Gault equation.\n3. Known or suspected infective endocarditis or active systemic infection.\n4. Clinically significant coagulation abnormalities, or anticipated inability to tolerate long-term antiplatelet therapy.\n5. Pregnant or breastfeeding women, women planning pregnancy within 1 year, or those unwilling to use effective contraception.\n6. Expected survival \\\u003C1 year.\n7. Allergy to iodinated contrast media.\n8. Prior coronary artery bypass grafting (CABG).\n9. Participation in another clinical trial within 3 months before enrollment, or current participation in another drug\u002Fdevice clinical trial without having reached its primary endpoint.\n10. Coronary angiography-based exclusion criteria:\n\n10.1 Non-IRA lesion with visually estimated diameter stenosis \\>90% and TIMI flow ≤2; 10.2 Complex coronary artery disease requiring CABG; 10.3 Angiography unable to clearly identify the infarct-related artery or non-infarct-related arteries.","100 Years",{"count":693,"type":22},1518,[61],"Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality, particularly in patients with multivessel coronary artery disease. Although primary percutaneous coronary intervention (PCI) has significantly improved short-term outcomes, these patients remain at high risk of recurrent cardiovascular events due to vulnerable non-culprit plaques. Coronary imaging techniques such as intravascular ultrasound (IVUS), optical coherence tomography (OCT), and angiography-derived indices (QFR, RWS) can identify high-risk lesions, but the optimal management strategy is still debated.\n\nEarly and intensive lipid-lowering therapy has been shown to stabilize atherosclerotic plaques. PCSK9 monoclonal antibodies, in combination with statins, provide rapid and profound LDL-cholesterol reduction and may enhance plaque stabilization beyond standard therapy. Small imaging studies suggest favorable effects of PCSK9 inhibitors on fibrous cap thickness and lipid burden, but their impact on clinical outcomes in AMI patients with multivessel disease remains uncertain.\n\nThis study aims to evaluate whether very early in-hospital administration of a PCSK9 inhibitor, in addition to standard care, can reduce major adverse cardiovascular events (MACE) over 12 months compared with standard lipid-lowering therapy alone. The trial will also explore imaging-based markers of plaque vulnerability and functional indices as secondary endpoints, in order to better understand the mechanisms linking lipid lowering, plaque stabilization, and clinical outcomes.",[28],[698],"Acute Myocardial Infarction; Multivessel Disease; PCSK9 Inhibitor; Lipid-Lowering Therapy; Plaque Vulnerability; MACE","2026-01-26",{"date":701,"type":40},"2026-01-27",{"date":500,"type":40},{"date":704,"type":22},"2028-10-31",{"name":706,"class":47},"Shanghai Zhongshan Hospital"]